

Fig. 3 Receiver-operating characteristic curve (ROC) analysis for BC and the probability of cancer-specific survival according to serum IgG levels of anti-calreticulin and MMP2 AAbs. The corresponding areas under the curves (AUC) of serum IgG levels of anti-calreticulin (A) and anti-MMP2 (B) AAbs in BC patients compared to normal controls were 0.65 and 0.59, respectively. Regarding cancer-specific survival in BC patients, a significant correlation was recognized with the IgG level of anti-MMP2 AAb (D), but not with anti-calreticulin AAb (C). N.S.: not significant

Table 3 *Multivariate Cox proportional hazards regression analyses for prediction of recurrence and survival of bladder cancer patients*

	Recurrence-free survival			Cancer-specific survival		
	HR	95% CI	*P*	HR	95% CI	*P*
Anti-MMP2 AAb	0.77	0.33 - 1.81	N.S.	2.62	1.04 - 6.58	0.04
Gender	0.93	0.46 - 1.88	N.S.	1.41	0.66 - 3.02	N.S.
Pathological stage	1.34	0.65 - 2.79	N.S.	3.25	1.23 - 8.58	0.02
Histological grade	1.51	0.65 - 3.50	N.S.	0.83	0.31 - 2.20	N.S.
Lymphovascular invasion	0.74	0.25 - 2.22	N.S.	0.40	0.12 - 1.37	N.S.
Nodal status	1.01	0.22 - 4.55	N.S.	0.49	0.10 - 2.46	N.S.

HR: hazard ratio, CI: confidence interval, N.S.: not significant.
Multivariate Cox proportional hazards regression analysis was used to estimate HR, with the corresponding 95% CI.

cancer patients (2, 5, 9). Interestingly, it has been suggested that there is a significant correlation between calreticulin expression and the aggressiveness of BC. The BC cells with calreticulin knockdown showed the suppression of proliferation, migration, and attachment, in contrast to the overexpression of calreticulin which enhanced cell migration and attachment (28). In BC tissues, calreticulin expression was predominant in the cytoplasm of BC cells, and its expression was higher in BC cells than in normal

urothelial cells (21). Furthermore, higher levels of calreticulin were found in urine samples of patients with BC, but not in urological patients without BC, and urinary calreticulin has been proposed as a biomarker of BC (20). Although it was reported that the detection sensitivity of serum calreticulin in BC patients was 73.0% (21), this is slightly higher than that in our present anti-calreticulin AAb study. However, Heo *et al.* reported that serum tumor-associated AAbs can be detected in the early stage of BC before serum tumor-associated antigens are detectable (19). Although calreticulin overexpression in tumor cells is well known, the mechanism of this increase have not been well defined. Previous studies reported an elevated serum IgG level of anti-calreticulin AAb in patients from hepatocellular carcinoma, gallbladder adenocarcinoma, pancreatic adenocarcinoma, and breast cancer when compared to healthy controls (10, 34). These data are concordant with our present results, suggesting that humoral immunity against calreticulin may be associated with the overexpression of calreticulin.

Matrix metalloproteinases play important roles in various tumorigenic processes, such as extracellular matrix remodeling, angiogenesis, apoptosis, epithelial-to-mesenchymal transition, and cell proliferation. MMP2 (gelatinase A, 72 kDa gelatinase) is one of the enzymes of the matrix metalloproteinase family, known to be essential for the degradation of type IV collagen in tumor tissues (41). Elevation of MMP2 has been reported in cancer tissues or sera from patients with breast, lung, gastric, ovarian, and bladder cancers. An association between the expression levels and clinicopathological factors was also described (12–14, 29, 37–39, 43). In BC, it has been reported that the overexpression of MMP2 was detected in biological samples, including tissue, sera, and urine, and associated with clinicopathological factors and/or a poorer prognosis (13, 14, 43). In BC tissues, MMP2 expression was detected mostly in the cytoplasm of BC cells, and its overexpression may be an independent prognostic biomarker for BC progression (43). A majority of biomarker studies including MMP2 in patients with BC have focused on urine (35). No detailed study on the detection sensitivity of serum/plasma MMP2 levels in BC patients has been conducted. The diagnostic sensitivity of our present study for serum anti-MMP2 AAb in BC patients was 60.0%, being higher than that for urinary MMP2 (51.0%). Therefore, we expect that MMP2 and its AAb in biological samples have the potential to be tumor markers for BC. To our knowledge, this is the first report regarding the sero-diagnostic potential of AAbs to calreticulin and MMP2 in BC. Our results demonstrated that serum IgG levels of anti-calreticulin and MMP2 AAbs may be serological biomarkers for BC and, in addition, anti-MMP2 AAbs were associated with the histological grade of the tumor and cancer-specific survival of BC patients.

In conclusion, we identified several secreted proteins that were recognized by AAbs in the sera of BC patients by proteomic analysis. We also revealed that serum IgG levels of anti-calreticulin and -MMP2 AAbs were significantly higher in BC patients than in normal controls. In addition, a higher serum IgG level of anti-MMP2 AAb was associated with a high-grade tumor and poorer prognosis of BC patients. These data suggest that serum anti-calreticulin and MMP2 AAbs may be candidate sero-diagnostic and/or -prognostic markers for BC patients.

Acknowledgements

This study was supported in part by a Grant-in-Aid for Scientific Research C (23590414) from the Japan Society for the Promotion of Science and the 2013–2014 Project Study from the Graduate School of Medical Sciences and the Research Project (No.2013-1004) from the School of Allied Health Sciences, Kitasato University.

REFERENCES

1. Bas WG van Rhijn, Henk G van der Poel, Theo H van der Kwast (2009) Cytology and urinary markers for the diagnosis of bladder cancer. *Eur Urol Suppl* **8**, 536–541.
2. Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M, Sanchez JC, Frutiger S, Hughes G, Pallini V, Hochstrasser DF and Tosi P (1997) Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. *Electrophoresis* **18**, 2832–2841.
3. Borden LS Jr, Clark PE and Hall MC (2003) Bladder cancer. *Curr Opin Oncol* **15**, 227–233.
4. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S and Tainsky MA (2006) Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. *Cancer Res* **66**, 1181–1190.
5. Chen CN, Chang CC, Su TE, Hsu WM, Jeng YM, Ho MC, Hsieh FJ, Lee PH, Kuo ML, Lee H and Chang KJ (2009) Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. *Ann Surg Oncol* **16**, 524–533.
6. Diamandis EP (2004) How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer. *Clin Chem* **50**, 793–795.
7. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB,

Moe R and Cheever MA (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. *Cancer Res* **54**, 16–20.
8. Coppolino MG, Woodside MJ, Demaurex N, Grinstein S, St-Arnaud R and Dedhar S (1997) Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. *Nature* **386**, 843–847.
9. Du XL, Hu H, Lin DC, Xia SH, Shen XM, Zhang Y, Luo ML, Feng YB, Cai Y, Xu X, Han YL, Zhan QM and Wang MR (2007) Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. *J Mol Med (Berl)* **85**, 863–875.
10. Erić-Nikolić A, Milovanović Z, Sánchez D, Pekáriková A, Džodić R, Matić IZ, Tučková L, Jevrić M, Buta M, Rašković S and Juranić Z (2012) Overexpression of calreticulin in malignant and benign breast tumors: relationship with humoral immunity. *Oncology* **82**, 48–55.
11. Fernández Madrid F (2005) Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. *Cancer Lett* **18**, 187–198.
12. Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C, Onisto M, Micela M, Stetler-Stevenson WG and Liotta LA (1992) Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. *Cancer Res* **52**, 4548–4549.
13. Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D and Loening SA (2001) Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. *Urology* **57**, 675–679.
14. Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S and Nakajima M (1996) Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. *Cancer* **78**, 2379–2387.
15. Goshima N, Kawamura Y, Fukumoto A, Miura A, Honma R, Satoh R, Wakamatsu A, Yamamoto J, Kimura K, Nishikawa T, Andoh T, Iida Y, Ishikawa K, Ito E, Kagawa N, Kaminaga C, Kanehori K, Kawakami B, Kenmochi K, Kimura R, Kobayashi M, Kuroita T, Kuwayama H, Maruyama Y, Matsuo K, Minami K, Mitsubori M, Mori M, Morishita R, Murase A, Nishikawa A, Nishikawa S, Okamoto T, Sakagami N, Sakamoto Y, Sasaki Y, Seki T, Sono S, Sugiyama A, Sumiya T, Takayama T, Takayama Y, Takeda H, Togashi T, Yahata K, Yamada H, Yanagisawa Y, Endo Y, Imamoto F, Kisu Y, Tanaka S, Isogai T, Imai J, Watanabe S and Nomura N (2008) Human protein factory for converting the transcriptome into an in vitro-expressed proteome. *Nat Methods* **5**, 1011–1017.
16. Gumus E, Erdamar S, Demirel G, Horasanli K, Kendirci M and Miroglu C (2004) Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. *Int J Urol* **11**, 1070–1077.
17. Hanash S (2003) Harnessing immunity for cancer marker discovery. *Nat Biotechnol* **21**, 37–38.
18. Hayashi E, Kuramitsu Y, Okada F, Fujimoto M, Zhang X, Kobayashi M, Iizuka N, Ueyama Y and Nakamura K (2005) Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. *Proteomics* **5**, 1024–1032.
19. Heo CK, Bahk YY and Cho EW (2012) Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. *BMB Rep* **45**, 677–685.
20. Kageyama S, Isono T, Matsuda S, Ushio Y, Satomura S, Terai A, Arai Y, Kawakita M, Okada Y and Yoshiki T (2009) Urinary calreticulin in the diagnosis of bladder urothelial carcinoma. *Int J Urol* **16**, 481–486.
21. Kageyama S, Isono T, Iwaki H, Wakabayashi Y, Okada Y, Kontani K, Yoshimura K, Terai A, Arai Y and Yoshiki T (2004) Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. *Clin Chem* **50**, 857–866.
22. Kakehi Y, Hirao Y, Kim WJ, Ozono S, Masumori N, Miyanaga N, Nasu Y and Yokomizo A (2010) Bladder Cancer Working Group report. *Jpn J Clin Oncol* **40**, 57–64.
23. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, Sesterhenn IA, Tachibana M and Weider (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. *Urology* **66**, 4–34.
24. Kobold S, Luetkens T, Cao Y, Bokemeyer C and Atanackovic D (2010) Prognostic and diagnostic value of spontaneous tumor-related antibodies. *Clin Dev Immunol* **2010**, 721531
25. Kulasingam V and Diamandis EP (2007) Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. *Mol Cell Proteomics* **6**, 1997–2011.
26. Liu R, Gong J, Chen J, Li Q, Song C, Zhang J, Li Y, Liu Z, Dong Y, Chen L and Jin B (2012) Calreticulin as a potential diagnostic biomarker for lung cancer. *Cancer Immunol Immunother* **61**, 855–864.
27. Lou X, Xiao T, Zhao K, Wang H, Zheng H, Lin D, Lu Y, Gao Y, Cheng S, Liu S and Xu N (2007) Cathepsin D is secreted from M-BE cells: its potential role as a biomarker of lung cancer. *J Proteome Res* **6**, 1083–1092.
28. Lu YC, Chen CN, Wang B, Hsu WM, Chen ST, Chang KJ, Chang CC and Lee H (2011) Changes in tumor growth and metastatic capacities of J82 human bladder cancer cells suppressed by down-regulation of calreticulin expression. *Am J Pathol* **179**, 1425–1433.
29. Monig SP, Baldus SE, Hennecken JK, Spiecker DB, Grass G, Schneider PM, Thiele J, Dienes HP and Hölscher AH (2001) Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. *Histopathology* **39**, 597–602.
30. Nagashio R, Sato Y, Jiang SX, Ryuge S, Kodera Y, Maeda T and Nakajima T (2008) Detection of tumor-specific autoantibodies in sera of patients with lung cancer. *Lung Cancer* **62**, 364–373.
31. Nanney LB, Woodrell CD, Greives MR, Cardwell NL, Pollins AC, Bancroft TA, Chesser A, Michalak M, Rahman M, Siebert JW and Gold LI (2008) Calreticulin enhances porcine wound repair by diverse biological effects. *Am J Pathol* **173**, 610–630.
32. Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH and Ho DM (2010) Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. *Am J Clin Pathol* **133**, 788–795.
33. Pavlou MP and Diamandis EP (2010) The cancer cell secretome: a good source for discovering biomarkers? *J Proteomics* **10**, 1896–1906.
34. Pekáriková A, Sánchez D, Palová-Jelínková L, Simsová M, Benes Z, Hoffmanová I, Drastich P, Janatková I, Mothes T, Tlaskalová-Hogenová H and Tucková L (2010) Calreticulin is a B cell molecular target in some gastrointestinal malignancies. *Clin Exp Immunol* **160**, 215–222.

35. Roy R, Yang J and Moses MA (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. *J Clin Oncol* **27**, 5287–5297.
36. Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, Türeci O, Sahin U, Pfreundschuh M and Old LJ (1998) Characterization of human colon cancer antigens recognized by autologous antibodies. *Int J Cancer* **76**, 652–658.
37. Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W and Lengyel E (2001) Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. *Clin Cancer Res* **7**, 2396–2404.
38. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB and Verspaget HW (1996) Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. *Br J Cancer* **74**, 413–417.
39. Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, Arciero C, Russell S, Garguilo G, Hooke J and Somiari RI (2006) Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. *Cancer Lett* **20**, 98–107.
40. Stastna M and Van Eyk JE (2012) Secreted proteins as a fundamental source for biomarker discovery. *Proteomics* **12**, 722–735.
41. Szarvas T, vom Dorp F, Ergün S and Rübben H (2011) Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. *Nat Rev Urol* **8**, 241–254.
42. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, Reich O, Rouprêt M, Shariat SF and Zlotta AR (2011) Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. *Eur Urol* **60**, 484–492.
43. Vasala K, Pääkkö P and Turpeenniemi-Hujanen T (2003) Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. *Urology* **62**, 952–957.
44. Volpe A, Racioppi M, D'Agostino D, Cappa E, Gardi M, Totaro A, Pinto F, Sacco E, Marangi F, Palermo G and Bassi PF (2008) Bladder tumor markers: a review of the literature. *Int J Biol Markers* **23**, 249–261.
45. Vougas K, Gaitanarou E, Marinos E, Kittas C and Voloudakis-Baltatzis IE (2008) Two-dimensional electrophoresis and immunohistochemical study of calreticulin in colorectal adenocarcinoma and mirror biopsies. *J BUON* **13**, 101–107.
46. Witjes JA and Hendricksen K (2008) Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. *Eur Urol* **53**, 45–52.
47. Wu CC, Chen HC, Chen SJ, Liu HP, Hsieh YY, Yu CJ, Tang R, Hsieh LL, Yu JS and Chang YS (2008) Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. *Proteomics* **8**, 316–332.
48. Xue H, Lu B and Lai M (2008) The cancer secretome: a reservoir of biomarkers. *J Transl Med* **17**, 52.
49. Yoon GS, Lee H, Jung Y, Yu E, Moon HB, Song K and Lee I (2000) Nuclear matrix of calreticulin in hepatocellular carcinoma. *Cancer Res* **60**, 1117–1120.
50. Zhong L, Peng X, Hidalgo GE, Doherty DE, Stromberg AJ and Hirschowitz EA (2004) Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. *Proteomics* **4**, 1216–1225.

Development of a protein array for autoantibody profiling of blood

— Comprehensive disease diagnosis using the body's defense system —

Yoshitaka KAWAKAMI[1] and Naoki GOSHIMA[2]*

[Translation from *Synthesiology*, Vol.7, No.3, p.154-162 (2014)]

We have developed infrastructure of the technologies and resources for post-human genome research to perform functional proteomics (the analysis of protein functions, protein-protein interactions, and human protein structures) on a large scale. A method for profiling autoantibodies in serum is developed using human protein expression resources and protein expression techniques. The human biological defense system responds to abnormalities in the body with extraordinary sensitivity. Hence, this system is an effective tool for detecting human diseases at an early stage. Health safety and security can be achieved by establishing an early diagnostic method for diseases using autoantibody profiling of blood with a protein array.

Keywords : Autoantibody, protein array, human protein, body's defense system, antigens, diagnosis, biomarker

1 Introduction

The ability to diagnose a disease before its development or at an early stage and obtaining a general diagnosis in which as much health information can be obtained in a single test is an extremely important issue in achieving a safe and secure society. In this research, we aim to achieve this objective by analyzing the types and quantities of autoantibodies in one drop of blood. Originally, the antibody is a biological defense system acquired by higher-order organisms through evolution, to defend themselves against bacteria and virus invasions. The antibody system is known to produce autoantibody against its own protein in response to the abnormal release of protein from cells or to the excessive production of proteins due to disease, as well as against external antigens. We think it is reasonable to utilize the biological defense mechanism that responds sensitively to the abnormalities of the body to detect diseases. Particularly, since the autoimmune diseases occur due to the production of antibodies that attack their own cells or tissues, the autoantibodies can be the cause of disease as well as disease markers. The detection of autoantibodies may enable presymptomatic testing for autoimmune diseases, thereby allowing early treatment. However, in practice, comprehensive tests for autoantibodies have not been established, and in most cases, one visits a hospital only after the symptoms of autoimmune diseases develop. There are also several intractable diseases in which the involvement of autoantibodies is suspected, and the development of a comprehensive detection system for autoantibodies is extremely important. There are many papers that reported the use of autoantibodies as disease markers for diseases including diabetes, cancer, Alzheimer's disease, rheumatism, and dilated cardiomyopathy.[1] We developed a comprehensive detection system of autoantibodies and have correlated the autoantibodies and diseases, by preparing antigen proteins using the world's largest human protein expression resource and a human protein synthesis technology that we have been working on for a long time. We hope to further the technological development for a comprehensive profiling of blood autoantibodies that are individually different and are closely related to health.

2 Construction of a human protein expression resource and its use

Based on the human full-length cDNA sequencing project of the Ministry of International Trade and Industry (currently Ministry of Economy, Trade and Industry) that was started in 1998, we started preparations for the following in the Protein Function Analysis Project of the New Energy and Industrial Technology Development Organization (NEDO) in 2000: (1) Human Proteome Expression (HUPEX) resource, (2) high-throughput protein synthesis technology, and (3) Human Gene and Protein Database (HGPD). At the time, the Human Genome Project to decode the genome DNA sequence was being done internationally, and taking the lead for the coming age of proteomics, Japan decided to fortify the environment for human genome research, constructed the HUPEX resource, and built a database.[2][3] The preparations of the technological foundation to carry out large-scale analyses of human protein functions, protein interactions, and protein structures were conducted as national projects. As a result, the HUPEX resource was utilized in various national research

1. Japan Biological Informatics Consortium TIME24 Bldg. 10F, 2-4-32 Aomi, Koto-ku 135-8073, Japan, 2. Molecular Profiling Research Center for Drug Discovery, AIST 2-4-7 Aomi, Koto-ku 135-0064, Japan * E-mail: n-goshima@aist.go.jp

Original manuscript received July 17, 2013, Revisions received January 27, 2014, Accepted January 27, 2014

projects, joint research with corporations, and academic joint researches with research institutes and universities, and yielded rich results in the respective fields. One of the major results was a joint project "Special Project for Yamanaka iPS Cell" of the Japan Science and Technology Agency (JST) with Dr. Shinya Yamanaka, Director of the Center of iPS Cell Research and Application (CiRA), Kyoto University. This project led to the new discovery of Glis1, a gene for promoting the induction of iPS cells.[4] Moreover, in the joint research with the School of Medicine, Gifu University, a factor to highly efficiently induce iPS cells was discovered from the dental pulp cells in teeth. In the joint study with the School of Medicine, Keio University, a factor to promote direct reprogramming where the myocardial cells can be made from heart fibroblasts was discovered. Many results were obtained in the search for factors that may be useful in regenerative medicine. Also, major results were obtained in the development of *in vitro* visualization technology of protein interaction for a drug discovery screening system, and the development of production of standard proteins for quantitative proteomics by mass spectrometer. Such research results were expected in the initial conceptualization of the HUPEX resource uses. The HUPEX resource technology that we have constructed so far was basically to support the smooth progress of industrial proteome research. Sometimes, as we deepen our research in a discipline, new horizons that we did not initially consider begin to unfold. When we climbed the mountain of the proteome study and looked back, we realized that we could study the comprehensive antibody fields when the protein groups that comprise the proteome are considered as antigens. As shown in Fig. 1, we could study the immunome (whole immune system) from the proteome (while not all antigens are proteins, they comprise a major part). The idea of comprehensively analyzing the autoantibody in blood using the HUPEX resource and applying it in diagnosis (Fig. 2) was not considered initially. However, we were capable of using more human proteins as antigens than any other researcher in the world, and we possessed the ability to use the resource to find out whether the antibodies are present in the blood serum. Many researchers have previously reported the idea of using the autoantibodies in the blood serum.[1] However, since it was difficult to prepare the antigens to detect the antibodies, comprehensive analysis of autoantibody had not been done until now. Currently, we are able to conduct the world's most accurate profiling of the blood serum autoantibody using the HUPEX resource. To realize autoantibody profiling, in addition to the HUPEX resource, it was necessary to establish a comprehensive protein expression technology, a technology for manufacturing protein arrays, and an antibody detection method. These technologies will be explained below.



Fig. 1 From proteome to immunome



Fig. 2 Autoantibody and disease

3 Development of a protein array that allows autoantibody profiling

3.1 Comprehensive human proteome expression resource and protein expression technology

We constructed a protein expression resource by introducing the Gateway cloning technology, a general-use cloning system, and created the plasmid DNA (entry clone) with site-specific recombination sequence at both ends of the open reading frame (ORF) of cDNA.[2] In the Gateway cloning technology, the expression clone can be created simply by mixing the entry clone and the destination vector, and by conducting site-specific DNA recombination using the recombination enzyme in a test tube. This is an optimal DNA recombination technology when conducting high-throughput protein expression.[5] This resource is the world's largest protein expression resource that covers about 80 % of the human genome,[2] and is named the HUPEX resource. Two types of entry clones were created: the N-type entry clone where the same amino acid sequence can be synthesized as the native protein at the C terminal per cDNA; and the F-type where the stop codon is replaced with a sense codon so a tag can be attached to the C terminal.[6] Various types of ORF type entry clones were created including the full-length ORF type with whole ORF for the gene, processing ORF type where the signal peptides were eliminated from the full-length ORF, and the domain ORF that could express the extracellular domain or intracellular domain with membrane protein with single membrane penetration domain. These resources can be freely selected according to the research objective. Also, since the protein synthesis can be conducted with all types of protein synthesis systems, the SD (Shine-Dalgarno) sequence for *E. coli* expression and Kozak sequence for eukaryotic cell expression was added to the 5' upstream of ORF. For these protein expression resources, the N-type and F-type entry clones were prepared, and about 60,000 types were created including the known and unknown clones, as well as the splicing variant clones (Table 1). To use these entry clones in a comprehensive proteome research, a clone with the longest ORF is selected for each gene as a representative clone, and they are functionally categorized according to the functions of proteins (transcription factor group, GPCR group, kinase group, unknown gene group, etc.). About 20,000 clones representing human genes were used in our research.

Table 1. Number of manufactured Gateway entry clones

Type	Determined number of entry clones	
	C terminal stop	C terminal fusion
Full-length ORF	18,744	28,386
Processing ORF	4,068	2,863
Domain ORF	2,719	-
Total	25,531	31,249
	56,780	



To conduct the comprehensive proteome research using human proteins, the technology to comprehensively synthesize the protein is necessary, as well as building the HUPEX resource. Around the year 2000 when we started constructing the protein expression resource, at the same time, Professor Yaeta Endo *et al.* of the Ehime University developed a wheat germ cell-free protein synthesis system.[7] We developed the technology for high-throughput protein synthesis using the wheat germ cell-free protein synthesis system (Fig. 3). The wheat germ cell-free protein synthesis system was superior in the points of success rate of protein synthesis, solubilization rate of the synthesized protein, and activity maintenance rate of the synthesized protein compared to other protein synthesis systems using *E. coli* or eukaryotic cells, and the protein could be synthesized at the percentage of 98 % or higher.[6] The whole reaction from DNA structuring to protein synthesis was done in an *in vitro* system (96 hole or 384 hole plate), and the reaction was optimized so only the dispensing procedure where the reacted solution was transferred to the next reaction solution was necessary. As a result, we developed a technology where the whole process of protein synthesis could be completed in



Fig. 3 Wheat germ cell-free protein synthesis system using the Gateway entry clone
Note) Modification of Fig. 6 in N. Goshima *et al.*: Constructing the foundation for comprehensive expression of human proteins, *Jpn. J. Exp. Med. (Extra no.)*, 23 (4), Chap. 3, Sec. 3, Yodosha (2005) (in Japanese).

one week. The LR product, PCR product, and mRNA that are created in the process of protein synthesis can be stored for a long period at -80 °C. In case it becomes necessary to resynthesize the same protein, it can be resynthesized in 18 hours using the stored mRNA. By combining the protein synthesis technology and a dispenser, it became possible to synthesize about 20,000 protein types at one time, and all proteins can be used in the simultaneous assay system through the array technology.

The results of the genetic information of the entry clones, the status of clones, and the results of protein expression of the wheat germ cell-free system or *E. coli* system are stored in the Human Gene and Protein Database (HGPD: http//www.HGPD.jp/), and they can be searched freely. The created entry clones are available from the National Biological Resource Center (NBRC), National Institute of Technology and Evaluation (NITE) (http://www.nbrc.nite.go.jp/hgentry.html).[3][8]

3.2 Development of the protein array technology

The protein array technology is useful in comprehensively analyzing the interactions of protein-protein, protein-low molecule, protein-nucleic acid, etc., as well as for analyzing the enzyme-substrate protein. In a conventional protein array, the protein is fixed on the nitrocellulose membrane sheet, or on the surface of the slide glass coated or specially treated with nitrocellulose. Due to the nature of the fixing method, the protein is fixed in a dehydrated condition on the substrate surface, and the three-dimensional structure is not maintained. Therefore, with the conventional array, the function of the fixed protein cannot be analyzed. We aimed to recreate and analyze the biological reaction on the array using the HUPEX resource and the high-throughput protein synthesis technology that we developed. For this purpose, it was necessary to find a way to fix proteins on the array substrate in a condition where the 3D structures were maintained and the proteins could express their functions on the array.

We developed a protein array where 3D structures and functions of the proteins were maintained. First, we focused on the protein refining technology using magnetic beads. By using our protein synthesis technology, the proteins can be synthesized with various tags attached. The target protein synthesized with tags can be easily refined using the magnetic beads with ligands. First, the target protein is bonded to the magnetic beads while maintaining the 3D structure at the time of synthesis. Normally, the protein bonded to the magnetic beads are eluted, recovered, and used, but we considered a way to create an array while maintaining the bond between the magnetic beads and the protein. A well plate for bonding with the magnetic beads was developed, and by combining the high-throughput protein synthesis technology and the protein refining and array technologies using the magnetic beads, we developed the technology for creating an array while maintaining the 3D structure of the protein (Fig. 4A). The protein array, in



Fig. 4A Manufacture of protein active array using magnetic beads and antibody detection

The GST-fused target protein synthesized by the wheat germ cell-free synthesis system is attached to the GSH magnetic beads surface. This suspension is dispensed into the magnetic plate (originally made) equipped with magnets at the bottom of the plate, and the non-adhering fraction is removed by cleansing. The protein active array with protein fixed using the magnetic beads in the solution is manufactured. The antibody (Y) or blood serum is added to the protein active array (PAA), the protein is bonded onto the array, and the bonded antibodies are detected by chemiluminescence using the HRP-fused secondary antibody.

Note) Modification of Fig. 3 in N. Goshima: Autoantibody analysis using the array, *Handbook of Therapeutic and Diagnostic Antibodies*, Chap. 1, Sec. 5, NTS (2012) (in Japanese).

which the panoramic analysis of protein function for human proteome can be conducted, is called the "protein active array (PAA)" (Fig. 4B).

In selecting the magnetic beads used for the PAA, it is necessary to compare various magnetic beads from the following perspectives: 1) type of ligand of magnetic beads, 2) material and size of the beads, 3) amount of adsorped target protein, 4) non-specific adsorption, and 5) method for dispensing the suspension. In general magnetic beads for His tag, GST tag, or Streptavidin tag adsorption are used. For the ligand of the magnetic beads, the GST tag adsorption magnetic beads was selected because the 5' FLAG-GST tag that allows creation of active expressed protein for protein synthesis was used. From the perspectives of aforementioned 2) to 5), we selected the glutatione particles of the MagneGST Protein Purification System (Promega Corporation).

When creating the PAA, a special well plate is necessary to which the magnetic beads bonded with expressed proteins can be fixed, and which does not require dispensers or other equipment when cleansing or supplying the common reagent. We developed a well plate for the PAA, where the magnet is installed at the bottom of the well and the thickness of the well bottom is made as thin as possible to allow the magnetic beads to bind strongly to the well bottom. Normally, in assays such as ELISA, each well uses independent plates, but for the magnetic beads array, the wells are designed to be independent of each other but the reaction of the solution made of diluted serum can take place without division between the wells. We also developed a special cover plate that prevents biohazards when handling the serum samples, and that allows the reaction to be accomplished with a small amount of homogenous solution. By placing this cover plate, the target proteins on the surface of magnetic beads are covered with minute quantity of reaction liquid using a syringe, and the blood serum sample can be handled in a closed system rather than an open system.

By devising the equipment as described above, the manufacture process of the PAA can be accomplished very simply and in a short time. First, proteins synthesized by the wheat germ cell-free protein synthesis method using 96 well plates are added to the magnetic beads, and the proteins are bound to the surface of the magnetic beads. The suspension of the magnetic beads bound to proteins is dispensed to the well plate of the PAA, the proteins adhere to the well plate by magnetic force of the magnetic beads, and the array is created for the target protein. In case of long-term storage, the storage liquid is added and is stored at -80 °C. As a result of storage tests, it was confirmed that the quality could be maintained for six months in the above storage condition.

3.3 Establishment of PAA detection method

The assay by PAA can be completed in about eight hours from the initial probe (serum, low molecular compound, proteins, etc. that will be investigated for the bond with human protein) reaction to detection. The number of samples that can be processed per day is four samples per person. For detection, secondary antibodies labeled with fluorescent pigment or secondary antibodies labeled with HRP for fluorescence detection are used. For detection, devices that can obtain the western blotting image can be used, such as the chemiluminescence image detector or fluorescence image detector that are commercially available. A liquid delivery pump is used for the cleansing process of the probe and the



Fig. 4B Panoramic analysis by PAA
Proteome-wide proteins are arranged as arrays on a substrate, serum or antibodies that act as probes are added, bonding of antibodies to human proteins are investigated panoramically, and the autoantibodies are monitored.

reaction solution, and these can be automated in the future.

3.4 Establishment of the screening method for PAA

We are capable of synthesizing about 20,000 types of proteins in a short time by combining the protein synthesis technology and the dispenser. To screen proteins efficiently and economically using these characteristics, it is necessary to achieve higher density of PAAs or higher efficiency of screening. Cost and labor are needed to manufacture the protein arrays using the 20,000 proteins that were expressed individually and to identify the antigens, and problems may arise in the practical use and measurement of multiple samples. Therefore, we thought we could reduce the cost and labor to about one-tenth by conducting primary screening by creating an array using a compound of 10 types of proteins, and then conducting secondary screening using only the protein compounds containing the hits.

Several manufacture methods of the mixture of 10 proteins were considered. The method whereby simply synthesizing 10 proteins independently and then mixing the individual proteins would require cost and labor. Therefore, we investigated in which phase of the protein synthesis the 10 proteins could be combined for the co-expression of 10 types of proteins. In our protein synthesis system explained above (Fig. 3), the protein syntheses are conducted by mixing 10 types of entry clones, LR reaction products, PCR products, and mRNAs from each reaction step. The expressed proteins are separated by the SDS-PAGE method, and are detected by the western blotting method. In the western blotting method, anti-GST HRP-linked mouse mono Ab (NACALAI) is added to the antibody, diluted 5,000 times in 1.0 % skim milk in PBST, antibody reaction done for five minutes using ECL plus (GE Healthcare), and chemiluminescence detection is done using the Fluor-SMAX (Bio-Rad Laboratories, Inc.). As a result, for the co-expression of 10 proteins, 10 protein types were expressed efficiently in the mixture after the PCR product. Considering the cost and the complexity of the maneuver, it is concluded that the protein synthesis should be done after manufacturing the 10 mixtures using the PCR products from the uppermost stream (Fig. 5).

Using the PAA manufactured from the 10 types of co-expressed proteins synthesized from the mixed PCR product, we conducted an investigation of antigen-antibody reaction for the antibody to determine the antigen. As a result, the antigen could be identified using the PAA manufactured using the 10 types of co-expressed proteins.

The two-step screening method, where the 10 types of proteins obtained in the primary screening or comprehensive PAA (C-PAA) using 10 types of co-expressed protein are individually used to conduct antigen identification in the secondary screening expanded PAA (E-PAA), was employed. The screening is simplified using this two-step screening method (Fig. 6).

Using this array technology, we manufactured PAAs for about 20,000 types of proteins that are categorized by function. The manufacturing technology of PAAs was transferred to Cell Free Sciences, Co. Ltd. that is working on the product realization of the PAAs.

3.5 Analysis of the autoantibody in the blood serum of a patient with ovarian carcinoma derived paraneoplastic cerebellar degeneration

Using the PAA, the analysis of the autoantibody in the serum of a paraneoplastic cerebellar degeneration (PCD) patient was conducted. The patient visited the Department of Neurology,



Sample no.	ID	5SG(STOP)	FLJ No	ORF Len (bp)	PCR product (bp)	MW(kDa)	Molecular weight of protein expressed by a native type entry clone
1	TEST0003	test clone No.56	FLJ21903	378	3105	14.7	44.4
2	TEST0001	test clone No.5	FLJ20819	624	3351	23.5	53.2
3	TEST0011	EGFP		720	3447	26.9	56.7
4	TEST0012	Venus-MGA		762	3489	28.2	58.0
5	TEST0009	Ubiquitin	FLJ34456	858	3585	33.3	63.0
6	TEST0007	kinase	FLJ34101	966	3693	37.0	66.7
7	TEST0008	phosphatase	FLJ34434	1176	3903	43.3	73.1
8	TEST0005	Transcription factor	FLJ16264	1374	4101	53.0	82.8
9	TEST0010	Autophosphorylation	FLJ37986	1638	4365	61.4	91.2
10	TEST0002	test clone No.8	FLJ20768	1842	4569	66.9	96.7

Fig. 5 Comparison of protein co-expression



Fig. 6 Antigen identification by C-PAA and E-PAA

The University of Tokyo Hospital, with numbness in the hands as an initial symptom. The patient's blood serum was diluted 1,000 times with PBS-T, and the autoantibody detection was conducted using the chemiluminescence detector using the HRP-labeled anti-human IgG antibody. From the detection results, about 37 types of autoantibodies were found (Fig. 7). The list of detected autoantibodies are shown as antigens in Table 2. LIMS1 and TRIM21 are autoantibodies that are detected highly frequently (80 % or higher) in healthy individuals. Although it has been reported that TRIM21 may be a marker antibody for lung cancer,[9] in our research, it was detected at high percentage (65 % or higher) in healthy individuals. Recently, the relationships to cancer have been reported for the SSX family of SSX1, SSX2, SSX3, SSX4B, and SSX5,[10] cancer antigens (CTA) CTA45A4 and CTA45A5, and lipase MGLL.[11] The antigen proteins of the autoantibodies detected this time were also reported to be related to cancer. On the other hand, IRX2 is a factor related to the formation of cerebellum,[12] and CTNNB2 is a protein related to the intercellular communication in the neurological connection.[13] From these findings, it was shown that the autoantibodies in the serum could be comprehensively detected using the PAA, and the antibodies related to cancer and cerebellar degeneration were detected. Since the cancer antibody was detected by the serum antibody analysis, the patient underwent thorough tests for cancer, and an ovarian tumor was found. It is not uncommon to find cancer in patients who visit the neurology department after experiencing some neurological symptoms. First, the cancer develops and several autoantibodies are produced as a result, and some of the autoantibodies may lead to neurological diseases. Currently, we are investigating whether these detected antibodies may become new biomarkers, by employing the JST Advanced Measuring and Equipment Development Program for 2012~2015 to obtain and analyze the autoantibody data of several patients and healthy subjects. If the autoantibody profiling can be done inexpensively and quickly using the PAA, it may be an extremely effective method for increasing the precision of various diagnoses.

4 Future issues

It is said that the antibodies are produced in large amounts, almost as much as the amplification of PCR against the



Fig. 7 Autoantibody detection from serum of patient with paraneoplastic neurological disease

Table 2. Autoantibody analysis of serum of patient with paraneoplastic neurological disease

Purified antibody no.	FLJ no.	GeneSymbol	Description
1	FLJ96281AAAF	DUSP11	dual specificity phosphatase 11 (RNA/RNP complex 1-interacting)
2	FLJ44773AAAF	A1BG	
3	FLJ81708AAAF	SSX2	synovial sarcoma, X breakpoint 2
4	FLJ81661AAAF	SSX1	synovial sarcoma, X breakpoint 1
5	FLJ82512AAAF	SSX3	synovial sarcoma, X breakpoint 3
6	FLJ81139AAAF	SSX5	synovial sarcoma, X breakpoint 5
7	FLJ13227AAAF	NXT2	nuclear transport factor 2-like export factor 2 (NXT2)
8	FLJ25823AAAF	CT45A4	cancer/testis antigen family 45, member A4
9	FLJ44051AAAF	LOC100128002	
10	FLJ13132AAAF	BAT5	
11	FLJ45293AAAF	CTNNA2	catenin (cadherin-associated protein), alpha 2
12	FLJ94954AAAF	LIMS1	LIM and senescent cell antigen-like domains 1
13	FLJ81000AAAF	SSX4B	synovial sarcoma, X breakpoint 4B
14	FLJ81065AAAF	TRIM21	tripartite motif-containing 21
15	FLJ96747AAAF	CD320	
16	FLJ96595AAAF	MGLL	
17	FLJ83136AAAF	CT45A5	cancer/testis antigen family 45, member A5
18	FLJ31021AAAF	LOC100129917	hypothetical protein LOC100129917
19	FLJ93657AAAF	RPL3L	ribosomal protein L3-like (RPL3L)
20	FLJ93363AAAF	MLLT3	myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 3
21	FLJ92129AAAF	RPL6	60S ribosomal protein L6
22	FLJ92146AAAF	RGS16	regulator of G-protein signaling 16
23	FLJ96402AAAF	RGS5	regulator of G-protein signaling 5
24	FLJ96688AAAF	RGS1	regulator of G-protein signaling 1
25	FLJ30022AAAF	RGS3	regulator of G-protein signaling 3
26	FLJ20416AAAF	NXF2B	nuclear RNA export factor 2B
27	FLJ31197AAAF		
28	FLJ37690AAAF		
29	FLJ39521AAAF		
30	FLJ38906AAAF		
31	FLJ25862AAAF		
32	FLJ27182AAAF		
33	FLJ44385AAAF		
34	FLJ56587AAAF		
35	FLJ41898AAAF		
36	FLJ82376AAAF	IRX2	Iroquois homeobox 2

➡ Cancer related ➡ Cerebellum related

amount of antigens. The antibodies circulate throughout the body through blood, and therefore, it is thought that minute changes in the body can be found by studying the antibodies. In fact, it is becoming possible to profile the changes in autoantibodies of the body using PAAs, and the autoantibody detection system is entering the practical phase in terms of technology.

In the future, the comprehensive detection system for autoantibody using PAAs will allow the autoantibodies to be profiled comprehensively for various diseases such as cancer and autoimmune diseases, and we hope to accumulate the data on the relationships between several diseases and autoantibodies. By doing this, we hope it will become possible to conduct an integrated test through autoantibody profiling of the blood, to allow the evaluations of progress and treatment of disease, early detection, policy for diagnosis and treatment, and therapeutic effects. In the development of PAAs, we are working on achieving higher density of protein arrays, and on finding economic ways of conducting highly sensitive measurement using small quantities of blood. We also wish to create a system that can be used easily in general hospitals and research facilities.

References

[1] R. H. Scofield: Autoantibodies as predictors of disease, *Lancet*, 363 (9420), 1544-1546 (2004).

[2] N. Goshima, Y. Kawamura, A. Fukumoto, A. Miura, R. Honma, R. Satoh, A. Wakamatsu, J. Yamamoto, K. Kimura, T. Nishikawa, T. Andoh, Y. Iida, K. Ishikawa, E. Ito, N. Kagawa, C. Kaminaga, K. Kanehori, B. Kawakami, K. Kenmochi, R. Kimura, M. Kobayashi, T. Kuroita, H. Kuwayama, Y. Maruyama, K. Matsuo, K. Minami, M. Mitsubori, M. Mori, R. Morishita, A. Murase, A. Nishikawa, S. Nishikawa, T. Okamoto, N. Sakagami, Y. Sakamoto, Y. Sasaki, T. Seki, S. Sono, A. Sugiyama, T. Sumiya, T. Takayama, Y.Takayama, H. Takeda, T. Togashi, K. Yahata, H. Yamada, Y. Yanagisawa, Y. Endo, F. Imamoto, Y. Kisu, S. Tanaka, T. Isogai, J. Imai, S. Watanabe and N. Nomura: Human protein factory for converting the transcriptome into an in vitro-expressed proteome, *Nat. Methods*, 5 (12), 1011-1017 (2008).

[3] Y. Maruyama, A. Wakamatsu, Y. Kawamura, K. Kimura, J. Yamamoto, T. Nishikawa, Y. Kisu, S. Sugano, N. Goshima, T. Isogai and N. Nomura: Human Gene and Protein Database (HGPD): a novel database presenting a large quantity of experiment-based results in human proteomics, *Nucl. Acids Res.*, 37 (suppl. 1), D762-D766 (2009).

[4] M. Maekawa, K. Yamaguchi, T. Nakamura, R. Shibukawa, I. Kodanaka, T. Ichisaka, Y. Kawamura, H. Mochizuki, N. Goshima and S. Yamanaka: Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1, *Nature*, 474, 225-229 (2011).

[5] J. L. Hartley, G. F. Temple and M. A. Brasch: DNA cloning using in vitro site-specific recombination, *Genome Res.*, 10, 1788-1795 (2000).

[6] Y. Kawamura, N. Goshima and N. Nomura: Human protein factory: an infrastructure to convert the human transcriptome into the in vitro-expressed proteome of versatile utility, *Tanpakushitsu Kakusan Koso*, 54 (9), 1173-1181 (2009) (in Japanese).

[7] K. Madin, T. Sawasaki, T. Ogasawara and Y. Endo: A highly efficient and robust cell-free protein synthesis system prepared from wheat embryos: Plants apparently contain a suicide system directed at ribosomes, *Proc. Natl. Acad. Sci. USA*, 97 (2), 559-564 (2000).

[8] Y. Maruyama, Y. Kawamura, T. Nishikawa, T. Isogai, N. Nomura and N. Goshima: HGPD: Human Gene and Protein Database, 2012 update, *Nucl. Acids Res.*, 40 (D1), D924-D929 (2012).
[9] M. Kuboshima, H. Shimada, TL. Liu, F. Nomura, M. Takiguchi, T. Hiwasa and T. Ochiai: Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma, *Cancer Sci.*, 97 (5), 380-386 (2006).
[10] B. J. Taylor, T. Reiman, J. A. Pittman, J. J. Keats, D. R. de Bruijn, M. J. Mant, A. R. Belch and L. M. Pilarski: SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs, *J Immunother.*, 28 (6), 564-575 (2005).
[11] E. Leah: Lipidomics: Growing on a free-fat diet, *Nat. Rev. Cancer*, 10, 160 (2010).
[12] K. Matsumoto, S. Nishihara, M. Kamimura, T. Shiraishi, T. Otoguro, M. Uehara, Y. Maeda, K. Ogura, A. Lumsden and T. Ogura: The prepattern transcription factor Irx2, a target of FGF8/MAP kinase cascade, is involved in cerebellum formation, *Nat. Neurosci.*, 7 (6), 605-612 (2004).
[13] M. Zhang, J. Zhang, SC. Lin and A. Meng: β-Catenin 1 and β-catenin 2 play similar and distinct roles in left-right asymmetric development of zebrafish embryos, *Development*, 139 (11), 2009-2019 (2012).

Authors

Yoshitaka KAWAKAMI



Withdrew from the doctorate course after obtaining the necessary credits from the Graduate School of Science, Osaka City University in 2008. Participated in the Regional Innovation Creation R&D Program "Development of Efficient Tumor Serum Marker by Random Immunization" and "Development of Comprehensive Diagnostic System for Specific Cancers Using Autoantibodies," as a technical staff at the Biomedicinal Information Research Center, AIST. Also worked in the "Multi-Institutional Pre-Phase II Clinical Trial for Post-Operative Esophageal Cancer Cases for CHP/NY-ESO-1 Polypeptide Cancer Vaccine" of the Ministry of Health, Labour and Welfare. Joined the Fukushima Medical Industrial Translational Research Project as a researcher of the Japan Biological Informatics Consortium from May 2013 to present. In this paper, was in charge of the creation of protein array and autoantibody measurement.

Naoki GOSHIMA

Completed the courses at the Department of Biochemistry, Graduate School of Agriculture and Biological Sciences, Osaka Prefecture University in 1987 (Doctor of Agricultural Science). Flexible Researcher, RIKEN; Assistant, Kyoto Pharmaceutical University; Assistant Professor, Graduate School of Science, Hiroshima University; and currently, Team Leader, Quantitative Proteomics Team, Molecular Profiling Research Center for Drug Discovery, AIST. Participated in the "Protein Function Analysis Project" of the New Energy and Industrial Technology Development Organization (NEDO) from 2000, and engaged in genome-wide protein functional analysis based on the Gateway creation of human full-length cDNA and comprehensive protein expression. Utilized the human protein expression resource and obtained results for the NEDO "Chemo-Bio Project," NEDO "TR Product," and "Special Project for Yamanaka iPS Cell" of Japan Science and Technology Agency in 2006. Engaged in the development of PAA in the Kyushu Regional Consortium in 2006 and the Kanto Regional Innovation in 2008~2010. Conducted the autoantibody profiling in blood sample to search for autoantibody biomarker. In this paper, was in charge of supervising the protein array research and collaboration with the medical practices.

Discussions with Reviewers

1 Overall comments

Question and comment (Yasushi Mitsuishi, AIST Tohoku)

I read this paper with interest, on the use of the results of the national project following from the human full-length cDNA project, and on the possibility of enabling early diagnosis of disease through blood serum autoantibody profiling that was not initially considered. I understood the idea that some kind of autoantibody is produced excessively in the development of a disease and that this can be used as a disease marker, but I felt the explanation of the technological result was too brief and I was somehow left unsatisfied. The paper seems to finish with the conclusion that you created a PAA that allows the comprehensive analysis of the bonded protein in blood serum. While it is great that you can do comprehensive analysis of proteins, but in this paper, please describe in detail the types of serum autoantibodies, the amount, and the level at which the presence and degree of disease can be estimated.

Answer (Naoki Goshima)

The detailed results described in the initial manuscript will be submitted to a specialized journal, including the consideration of autoantibody as a marker. Therefore, I responded to your comment by including the analysis of the autoantibodies in the blood serum of a patient with ovarian carcinoma derived paraneoplastic cerebellar degeneration as the data of the paper that focuses on the development of protein array technology.

2 Concept of PAA

Question and comment (Noboru Yumoto, AIST)

The objective of this research is "the development of a comprehensive detection system for autoantibodies," and centering on the major breakthrough of "the construction of the world's largest protein expression resource," the scenario, in which the elemental technologies including comprehensive protein expression technology, protein array technology, antibody detection technology, and screening technology were integrated, is understandable to the readers of the bio field. However, I think it is difficult for people outside the field to understand what actually is a proteome array. Therefore, can you include a conceptual diagram of the PAA that you developed?

Answer (Naoki Goshima)

I added the conceptual diagram of the PAA to Fig. 4B, and added explanations to the diagram, Fig. 4.